Study
A new study found that using sound therapy combined with tongue stimulation significantly improved tinnitus symptoms for adults with moderate or severe cases.
In plain language
Researchers have discovered that combining sound therapy with tongue stimulation can help reduce the symptoms of tinnitus, particularly in individuals experiencing moderate to severe cases. In a study involving 112 participants, those who received both sound and tongue stimulation reported greater improvements in their tinnitus symptoms compared to those who received sound therapy alone. This new approach, using a device called Lenire, led to a meaningful improvement in 58.6% of participants, compared to 43.2% with just sound therapy. This finding is promising for seniors dealing with bothersome tinnitus, offering a potential new treatment option to discuss with healthcare providers.
Use the full description to understand the study design, methods, and the limits of the findings.
A pivotal multi-site trial demonstrated that combining sound therapy with electrical tongue stimulation using the Lenire® device significantly improved tinnitus symptoms among adults with moderate to severe tinnitus, achieving a 58.6% responder rate compared to 43.2% with sound-only therapy. The study led to FDA De Novo approval of the Lenire device.
Open the original publication for the complete methods, outcomes, and source material.
Published November 2025
Opens at the publisher · external site · may require institutional access
The study provides moderate to strong evidence for the efficacy of combining sound with tongue stimulation for tinnitus treatment. While the design is robust for a single-arm trial, the lack of randomization and blinding introduces potential biases. The study is relevant to seniors but could benefit from more detailed age-specific analysis.
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 7.5/10 | |
| Bias & Methods | 6.5/10 | |
| Statistical Integrity | 8.0/10 | |
| Transparency | 8.0/10 | |
| Conflict of Interest Disclosure | 9.0/10 | |
| Replication / External Validation | 5.0/10 | |
| Relevance to Seniors | 7.0/10 | |
| Journal Quality | 9.0/10 |
The study's approval by the FDA De Novo process adds credibility, but further independent replication would strengthen the evidence base. The lack of serious adverse events is a positive aspect for senior safety.
Build a personalized plan using research-backed studies, conditions, and treatments.